Press releases

Annexin Pharmaceuticals AB (publ) announces that the U.S. Patent and Trademark Office has allowed an issue of the new patent, further strengthening the intellectual property and key coverage for the Annexin...

Annexin Pharmaceuticals has been given the go-ahead by FDA to start the planned phase 2 clinical trial with the drug candidate ANXV in patients with retinal vein occlusion (RVO). STOCKHOLM (5 April, 2022)...

Annexin Pharmaceuticals AB (publ) has entered into a license agreement with Stanford University, CA, USA granting Annexin Pharmaceuticals exclusive license to patent rights related to use of Annexin A5...

Annexin Pharmaceuticals AB (publ) announces that Dr Mario Fsadni, an ophthalmologist with extensive global experience from leading novel compounds through clinical development into marketed drugs, will...

 Maastricht University Hospital receives approvals to start study with Annexin Pharmaceuticals drug candidate, ANXV, in patients with COVID19.  STOCKHOLM, SWEDEN (January 19, 2022) – Annexin Pharmaceuticals AB ...